Authors
Latest:
Bispecific CD19/CD22 CAR T Cells Active in Pediatric Relapsed ALLTreatment with CD19/22 chimeric antigen receptor CAR T cells induced a promising response in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Latest:
More Research Needed to Understand COVID-19 Vaccine Effects in CAR T RecipientsFurther understanding of how COVID-19 vaccinations affect CAR T-cell therapy recipients is needed.
Latest:
BCMA/CD19 CAR T Shows Efficacy in Newly Diagnosed Multiple MyelomaUpdated data were presented at the ASH 2022 annual meeting.
Latest:
Februrary 2008 Clinical Trial ReportsThe Clinical Trials reported in this issue include: PHASE III: 1) What Factors Predict Prognosis in Patients With Malignant Pleural Mesothelioma? 2) Treatment for Patients With High-Risk Postoperative Breast Cancer PHASE II: 1) Epratuzumab Plus Rituximab Equals Non-Hodgkin's Lymphoma Response 2) Topotecan Added to Twice-Daily Chemoradiation to Treat Limited- Stage, Small-Cell Lung Cancer 3) First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer 4) Radiotherapy for Nasal Squamous Cell Carcinoma Therapy PHASE I/II: 1) A New Combination Approach for Advanced-Stage Germ-Cell Tumors
Latest:
Targeting Non-Mutant EGFR: Genetic and Clinical Biomarkers May Help Validate Use of InhibitorsA recent study suggests patients may be selected for therapy based on the number of EGFR gene copies, and evaluated for clinical benefit based on the severity of the rash that often develops.
Latest:
Gene Signatures Predict for Radiation Response in Breast CancerRecent studies have demonstrated that somatic mutations of ATM denote greater response to radiation therapy and that gene patterns may help predict the timing of recurrence following radiation.
Latest:
Stem Cell Therapy CALEC Restores Corneal Damage in Trial Led by Massachusetts Eye and Ear InvestigatorsCALEC completely restored the cornea in 50% of participants at their 3-month visit and that rate of complete success increased to 79% and 77% at their 12- and 18-month visits, respectively.
Latest:
Topical Gene Therapy B-VEC Improves Vision in Compassionate Use ProgramKrystal Biotech's B-VEC was well-tolerated and the treated patient experienced significant improvement in visual acuity.
Latest:
The State of Retina TherapeuticsAn international panel of experts discussed needs and challenges in the field.
Latest:
Gene therapy for wet AMD shows promising long-term resultsThree-year follow-up from the phase I/IIa trial of rAAV.sFlt-1 subretinal injection is encouraging for gene therapy for exudative age-related macular degeneration.
Latest:
Gene therapy for choroideremia may be on horizonGene therapy to treat choroideremia is one step closer to reality thanks to a new study.
Latest:
Researchers Highlight Potential of Gene Editing in Inherited Retinal DiseasesStudies have demonstrated positive data that suggest in vivo gene editing will be the future treatment paradigm for retinal diseases.
Latest:
Inherited leber's congenital amaurosis gene therapy may be effectiveA novel gene therapy approach for the treatment of a type of inherited retinal disease appears to be safe and effective in initial trials. Results offer hope for the treatment of a gamut of eye diseases that once were thought to be untreatable, according to one researcher.
Latest:
Biologic agents treat ocular inflammatory diseaseEditor's Note: As defined by the FDA, the term "biologics" refers to a wide range of products that includes vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, such as monoclonal antibodies and antibody fragments.
Latest:
Biologic agents treat ocular inflammatory diseaseEditor's Note: As defined by the FDA, the term "biologics" refers to a wide range of products that includes vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, such as monoclonal antibodies and antibody fragments.
Latest:
Biologic agents treat ocular inflammatory diseaseEditor's Note: As defined by the FDA, the term "biologics" refers to a wide range of products that includes vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, such as monoclonal antibodies and antibody fragments.
Latest:
Biologic agents treat ocular inflammatory diseaseEditor's Note: As defined by the FDA, the term "biologics" refers to a wide range of products that includes vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins, such as monoclonal antibodies and antibody fragments.
Latest:
RGX-314 Shows Signs of Efficacy, Safety for Neovascular AMDNovel gene therapy demonstrates improved visual acuity and retinal thickness.
Latest:
CAR-T Cells: The Next Era in Immuno-OncologyAn update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Latest:
CAR-T Cells: The Next Era in Immuno-OncologyAn update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
Reimbursement and Managed Care News for January 2008Topics covered in this issue include:1) Dosing Patterns and Costs of Erythropoesis-Stimulating Agents in Patients With Cancer2) New Practice Guideline Updates Treatment of Nonâ%uFFFD%uFFFDSmall Cell Lung Cancer3) Large Health Insurer Begins Genetic Risk Counseling for Cancer4) Multiple Myeloma Guidelines Now Include Combination Therapy With Bortezomib5) Survey Finds That Managed Car Executives Are Misinformed About the Value and Cost of Cancer Biologics
Latest:
Evaluating Zamto-Cel in R/R DLBCLNirav Shah, MD, an associate professor of medicine at Medical College of Wisconsin, discussed efficacy data presented at the 2025 Tandem Meetings.
Latest:
Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in LymphomaIra Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.
Latest:
Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in LymphomaSattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.
Latest:
Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCLLori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.
Latest:
CAR T-Cell Therapy Enters a New Era in Lymphomas, But More Lessons to LearnBrian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.
Latest:
Axi-cel Approved by European Commission for Second-Line Treatment of Adults With DLBCL/HGBLThe approval was based on data from ZUMA-7, a phase 3 clinical trial.
